For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

Will be 4th acquisition for the US private equity giant in India’s healthsector in four months. Kedaara to make 5x rupee returns on exit.

Whenever there is a correction or volatility, just ask one question: Is it an opportunity, or should one be wary? We are raising this issue...

When a market starts rising and buying makes a comeback, something happens to a large majority of investors. They get restless. The safe, m...

A word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...

India's festive shopping season is set to highlight the country's premiumisation boom despite global uncertainty triggered by the US-Iran w...

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...

Following the sharp re-rating in small- and midcaps, Axis Mutual Fund has urged investors to revisit largecaps, saying their valuations hav...

PAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...

Sunil Singhania's Abakkus Asset Management added two new stocks and increased holdings. The firm acquired stakes in Afcom Holdings and TTK ...

Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...

Markets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...

Cipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...

Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...

The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...